Compare Gilead Sciences, Inc. (GILD) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Shell PLC — how do they compare? Gilead Sciences, Inc. trades at $133.06 (market cap $163.51B), while Shell PLC trades at $85.23 (market cap $228.96B). The key difference: Shell PLC is the larger of the two by market cap, and Shell PLC pays the higher dividend (3.69%). Which is the better fit depends on your goals.
| GILD | SHEL | |
|---|---|---|
Market Cap | $163.51B | $228.96B |
Sector | Health | Energy |
52-Week High | $155.80 | $94.15 |
52-Week Low | $108.22 | $70.28 |
Enterprise Value | $178.05B | $281.49B |
Dividend Yield | 2.49% | 3.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Shell (SHEL) trades at $84.41, up 0.51% on the day, with a bullish technical signal and strong analyst support. Recent Q1 2026 earnings beat expectations at $2.44 EPS, though revenue has trended down from $381.3B in 2022 to $266.9B in 2025. The stock shows attractive valuation with a P/E of 13.18 and P/S of 0.93, while news highlights the ARC Resources acquisition approval and Venezuela gas field development plans.
Outlook remains positive given high analyst buy ratings (69%) and a $122.20 consensus price target, but risks include declining operating cash flow, Middle East production disruptions, and exposure to volatile energy markets. Earnings growth and strategic acquisitions are key catalysts for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
